Immune-modulatory radiotherapy to enhance the effects of neo-adjuvant PD-L1 blockade after neo-adjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)
This “allocated fund in clinical research” was granted in December 2020 to Dr. Sacha Rothschild (University Hospital Basel) for 3 years.